Marimed Inc
MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States and internationally. The company sells cannabis flower, vapes, and concentrates under the Nature's Heritage brand; cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty's Eddies brand; and cannabis-infused ice creams under Emack & Bolio's bra… Read more
Marimed Inc (MRMD) - Net Assets
Latest net assets as of September 2025: $54.32 Million USD
Based on the latest financial reports, Marimed Inc (MRMD) has net assets worth $54.32 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($205.60 Million) and total liabilities ($151.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $54.32 Million |
| % of Total Assets | 26.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | 162.32% |
| 10-Year Change | N/A |
| Growth Volatility | 184.75 |
Marimed Inc - Net Assets Trend (2014–2024)
This chart illustrates how Marimed Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Marimed Inc (2014–2024)
The table below shows the annual net assets of Marimed Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $59.88 Million | -14.36% |
| 2023-12-31 | $69.91 Million | -26.43% |
| 2022-12-31 | $95.03 Million | +28.38% |
| 2021-12-31 | $74.02 Million | +224.30% |
| 2020-12-31 | $22.83 Million | +260.69% |
| 2019-12-31 | $6.33 Million | -89.75% |
| 2018-12-31 | $61.76 Million | +461.13% |
| 2017-12-31 | $11.01 Million | +2096.07% |
| 2016-12-31 | $-551.44K | +72.23% |
| 2015-12-31 | $-1.99 Million | -17.84% |
| 2014-12-31 | $-1.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Marimed Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10314710800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $173.75 Million | 281.93% |
| Total Equity | $61.63 Million | 100.00% |
Marimed Inc Competitors by Market Cap
The table below lists competitors of Marimed Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IS:KAPLM
|
$32.00 Million |
|
Footway Group AB Series B
ST:FOOT-B
|
$32.01 Million |
|
SWISS PROPERTIES INV.100
F:SR1
|
$32.01 Million |
|
Trakcja PRKiI S.A.
WAR:TRK
|
$32.02 Million |
|
Memscap Regpt
PA:MEMS
|
$31.99 Million |
|
MFEC PCL
BK:MFEC
|
$31.99 Million |
|
Digital Mediatama Maxima PT
JK:DMMX
|
$31.99 Million |
|
Unique Optical Industrial Co Ltd
TWO:3441
|
$31.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Marimed Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 71,564,000 to 61,628,000, a change of -9,936,000 (-13.9%).
- Net loss of 12,164,000 reduced equity.
- Dividend payments of 139,000 reduced retained earnings.
- Other factors increased equity by 2,367,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.16 Million | -19.74% |
| Dividends Paid | $139.00K | -0.23% |
| Other Changes | $2.37 Million | +3.84% |
| Total Change | $- | -13.88% |
Book Value vs Market Value Analysis
This analysis compares Marimed Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.00 | $0.10 | x |
| 2017-12-31 | $0.06 | $0.10 | x |
| 2018-12-31 | $0.29 | $0.10 | x |
| 2019-12-31 | $0.03 | $0.10 | x |
| 2020-12-31 | $0.07 | $0.10 | x |
| 2021-12-31 | $0.34 | $0.10 | x |
| 2022-12-31 | $0.39 | $0.10 | x |
| 2023-12-31 | $0.19 | $0.10 | x |
| 2024-12-31 | $0.16 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Marimed Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.70%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 3.36x
- Recent ROE (-19.74%) is above the historical average (-111.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -8189.97% | 0.05x | 0.00x | $-7.07 Million |
| 2015 | 0.00% | -95.68% | 0.34x | 0.00x | $-1.02 Million |
| 2016 | 0.00% | -5.58% | 0.42x | 0.00x | $-88.01K |
| 2017 | -11.02% | -19.68% | 0.19x | 2.97x | $-2.28 Million |
| 2018 | -21.95% | -114.78% | 0.14x | 1.34x | $-19.80 Million |
| 2019 | -1179.72% | -178.02% | 0.74x | 8.95x | $-81.87 Million |
| 2020 | 9.17% | 4.21% | 0.67x | 3.27x | $-195.20K |
| 2021 | 6.38% | 5.95% | 0.99x | 1.09x | $-4.11 Million |
| 2022 | 10.03% | 10.05% | 0.88x | 1.13x | $40.90K |
| 2023 | -22.40% | -10.79% | 0.76x | 2.74x | $-23.19 Million |
| 2024 | -19.74% | -7.70% | 0.76x | 3.36x | $-18.33 Million |
Industry Comparison
This section compares Marimed Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Marimed Inc (MRMD) | $54.32 Million | 0.00% | 2.78x | $32.00 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |